ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: biosimilars

EULAR 2015: What’s New in RA Research

  |  

ROME, Italy—Even with classification criteria that have been updated and refined over time, rheumatoid arthritis (RA) is still a diagnosis that ultimately has to be made with clinical judgment, said Ronald van Vollenhoven, MD, PhD, professor of medicine and chief of clinical therapy research in inflammatory diseases at the Karolinska University in Sweden. His remarks…

Ixekizumab Clinical Trials Continue; FDA Updates Warning Label for Varenicline

Michele B. Kaufman, PharmD, CGP, RPh  |  

It seems to have begun in Norway, the international pressure to switch patients from well-known brand biologic agents, such as Remicade (infliximab), to biosimilar agents, due to a significant cost advantage.1 This biosimilar came with a 39% price markdown last year compared with the brand, and when Norway called for bids, the discount went to…

Biologic Drugs for Psoriasis Are Rarely Stopped for AEs

Joan Raymond  |  

NEW YORK (Reuters Health)—Real-world psoriasis patients receiving biologic therapies rarely stop taking the drugs because of adverse effects, researchers say. Although data from long-term registries have shown similar results, “the demographics of patients in registries are somewhat different than those of patients in real-world practices,” Dr. Jensen Yeung told Reuters Health by email. “I have…

The ACR, Rheumatologists Advance Issues Through Advocacy

E. William St.Clair, MD  |  

Rheumatologists and rheumatology health professionals make a difference every day in the lives of patients. And through the work of many devoted members, the College takes that commitment beyond the care setting and into the policy arena to Advance Rheumatology! on Capitol Hill and in state capitols across the country. I want to take a…

First Biosimilar Drugs Approved in U.S., Canada

  |  

The first biosmilar products have been approved in the U.S. and Canada, following Europe’s early lead. Canada approved its first biosimilar monoclonal antibody (mAb) therapy, known as Inflectra (infliximab), on March 30, 2015.1 In Canada, biosimilars are being called subsequent entry biologic (SEB) agents. Inflectra is approved for treating patients with rheumatoid arthritis (RA), ankylosing…